NXTS Nexentis Technologies Inc.
$1.62▼ -4.14%
Materials
Other
After hours
$1.62▲ +0.00%
Sep 11, 7:30 PM ET
Volume 7.3K
Avg Volume (10D) 22.6K
Key Metrics & Fundamentals
Market Cap
$2.35M
P/E Ratio
0.2
Div Yield
–%
52W Range
1.43 - 53.41
% vs 50 MA
-24.79%
% vs 200 MA
-76.50%
RSI-14
35.9
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.65
Free Cash Flow
-$623,000
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.61M
COGS
–
Operating Exp
$1.74M
Operating Income
-$1.74M
EBIT
-$1.74M
Pretax Income
-$11.18M
Net Income
-$11.15M
EPS (Diluted)
-13.66
Price & Volume History
Loading chart…
Recent News
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
GlobeNewswire · Jul 28, 2026 12:06 PM
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
GlobeNewswire · Jul 7, 2026 12:25 PM
Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)
InvestorsHub · Jun 29, 2026 2:10 PM
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
GlobeNewswire · Jun 29, 2026 12:20 PM
Top Midday Decliners
MT Newswires · Jun 23, 2026 6:10 PM
Top Premarket Decliners
MT Newswires · Jun 23, 2026 11:35 AM
Top Midday Gainers
MT Newswires · Jun 22, 2026 6:07 PM
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
GlobeNewswire · Jun 22, 2026 12:22 PM
Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
GlobeNewswire · Jun 17, 2026 11:32 AM
Financial Overview - Income Statement
Quarterly
Sep 2025
See NXTS's money flow as a full page
Social Sentiment
No Reddit posts found for NXTS.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.